EP Patent

EP4064854A1 — Use of sglt-2 inhibitors in the drying-off of non-human mammals

Assigned to Boehringer Ingelheim Vetmedica GmbH · Expires 2022-10-05 · 4y expired

What this patent protects

The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off o…

USPTO Abstract

The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off of a non-human mammal, preferably ruminant, comprising administering to such non-human mammal, preferably ruminant, at least one SGLT-2 inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP4064854A1
Jurisdiction
EP
Classification
—
Expires
2022-10-05
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Vetmedica GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.